MURA
Mural Oncology PLC
$
1.750
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.765
Open
1.720
VWAP
1.73
Vol
397.20K
Mkt Cap
28.76M
Low
1.695
Amount
687.98K
EV/EBITDA(TTM)
--
Total Shares
17.32M
EV
-48.34M
EV/OCF(TTM)
--
P/S(TTM)
--
Mural Oncology plc is Ireland-based clinical-stage oncology company. The Company is leveraging its protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. It leverages its in-cytokine biology, immune cell modulation and protein engineering capabilities to develop immunotherapies. The Company is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available. Its portfolio of programs includes Nemvaleukin alfa (Nemvaleukin)-IL-2, IL-12, and IL-18. Nemvaleukin is an engineered interleukin-2 (IL-2) variant designed to harness the potent anti-cancer capabilities of high-dose rhIL-2 while minimizing toxicity by selectively activating cancer-fighting CD8 T cells and NK cells. The tumor-targeted split IL-12 program focuses on delivering the therapeutic potential of IL-12 by splitting it into inactive component.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
--
--
-0.810
-58.03%
--
--
-0.160
-92.04%
--
--
-0.300
-83.96%
Estimates Revision
The market is revising No Change the revenue expectations for Mural Oncology plc (MURA) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -34.21%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Down
-34.21%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for Mural Oncology PLC (MURA.O) is -0.35, compared to its 5-year average forward P/E of -0.59. For a more detailed relative valuation and DCF analysis to assess Mural Oncology PLC 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-0.59
Current PE
-0.35
Overvalued PE
-0.31
Undervalued PE
-0.86
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Fair
5Y Average EV/EBITDA
0.81
Current EV/EBITDA
0.86
Overvalued EV/EBITDA
1.53
Undervalued EV/EBITDA
0.09
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.10
Current PS
0.00
Overvalued PS
0.70
Undervalued PS
-0.50
Financials
Annual
Quarterly
FY2025Q2
YoY :
-8.52%
-31.36M
Operating Profit
FY2025Q2
YoY :
+52.01%
-47.98M
Net Income after Tax
FY2025Q2
YoY :
+49.46%
-2.78
EPS - Diluted
FY2025Q2
YoY :
+6.84%
-31.37M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
42.2K
USD
3
3-6
Months
23.8K
USD
3
6-9
Months
59.6K
USD
2
0-12
Months
42.2K
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 385.39% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
1
1.1M
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
42.2K
USD
3
3-6
Months
23.8K
USD
3
6-9
Months
59.6K
USD
2
0-12
Months
42.2K
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
MURA News & Events
Events Timeline
2025-08-04 (ET)
2025-08-04
08:05:19
Mural Oncology reports Q2 EPS ($2.78) vs ($1.86) last year
2025-04-15 (ET)
2025-04-15
08:07:54
Mural Oncology plans to explore strategic alternatives
2025-04-15
08:07:32
Mural Oncology to discontinue nemvaleukin development, reduce staff by 90%
Sign Up For More Events
Sign Up For More Events
News
8.5
04-15BenzingaMural Oncology Shares Surge As Company Explores Strategic Alternatives: What's Going On?
4.5
04-15BenzingaCrude Oil Moves Lower; Citigroup Posts Upbeat Results
4.5
04-15BenzingaNasdaq Surges 100 Points; Bank of America Earnings Top Views
Sign Up For More News
People Also Watch
GWH
ESS Tech Inc
1.685
USD
-2.03%
LITM
Snow Lake Resources Ltd
4.020
USD
-0.74%
FNGR
FingerMotion Inc
1.420
USD
0.00%
ELTX
Elicio Therapeutics Inc
9.830
USD
+4.57%
CCG
Cheche Group Inc
0.773
USD
0.00%
BOWN
Bowen Acquisition Corp
9.190
USD
+0.54%
BTCS
BTCS Inc
4.370
USD
-3.96%
VATE
Innovate Corp
4.710
USD
+0.64%
WFCF
Where Food Comes From Inc
11.430
USD
+2.51%
FAQ
What is Mural Oncology PLC (MURA) stock price today?
The current price of MURA is 1.75 USD — it has increased 5.42 % in the last trading day.
What is Mural Oncology PLC (MURA)'s business?
What is the price predicton of MURA Stock?
What is Mural Oncology PLC (MURA)'s revenue for the last quarter?
What is Mural Oncology PLC (MURA)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Mural Oncology PLC (MURA)'s fundamentals?
How many employees does Mural Oncology PLC (MURA). have?